目次
Table of Content
1. Personalized Cancer Vaccines As Next Generation Immunotherapeutic Approach
1.1 Approach To Cancer Vaccine Strategy
1.2 Cancer Vaccines - Current Progress and Challenges
2. Personalized Cancer Vaccine Mechanism Of Action
2.1 Role of Tumor Neoantigens and Human Leukocyte Antigen
2.2 Personalized Cancer Vaccine Working Mechanism
2.3 Genetic Polymorphism In Pharmacogenomics
2.4 Cancer Pharmacogenomics and Somatic Mutations
3. Role of Biomarkers In Personalized Vaccines
3.1 Pharmacogenomic Biomarkers
3.2 Prognostic and Predictive Biomarkers
4. Provenge - 1st Approved Personalized Cancer Vaccine
4.1 Overview and Patent Insight
4.2 Pricing and Dosing Insight
5. Personalized Cancer Vaccines Clinical Insight By Developer, Indication and Phase
6. Current Clinical Development and Future Commercialization Outlook
6.1 Current Market Development Scenario
6.2 Future Market Outlook
7. Personalized Cancer Vaccines Clinical Tends and Developments Insight By Indication
7.1 Melanoma
7.2 Lung Cancer
7.3 Breast Cancer
7.4 Prostate Cancer
7.5 Gastrointestinal Cancers
7.6 Gynecological Cancers
7.7 Brain Tumor
7.8 Hematological Malignancies
8. Personalized Cancer Vaccines Clinical and Market Insight By Region
8.1 US
8.2 EU
8.3 China
8.4 India
8.5 Australia
8.6 South Korea
8.7 Taiwan
8.8 UK
9. Personalized Cancer Vaccines Proprietary Development Platforms
9.1 BioNTech - iNeST
9.2 BioVaxys - DPX and Haptenix Platforms
9.3 CureVac - proprietary mRNA technology
9.4 Evaxion - PIONEER and ObsERV Technologies
9.5 Geneos - GT-EPICandtrade; platform
9.6 Moderna - mRNA Design Studio
9.7 myNEO Therapeutics - ImmunoEngine
9.8 Nouscom - Unnamed Technology
9.9 Nykode Therapeutics - Vaccibody
9.10 Transgene - myvac
10. Personalized Cancer Vaccine Market Dynamics
10.1 Market Drivers and Opportunities
10.2 Market Challenges and Restraints
11. Competitive Landscape
11.1 BioNtech AG
11.2 CureVac AG
11.3 Evaxion Biotech
11.4 Geneos Therapeutics
11.5 Genentech
11.6 Merck
11.7 Moderna Therapeutics
11.8 NeoCura
11.9 Transgene
11.10 TuHURA Biosciences
List of Figures & Tables
Figure 1-1: Cancer Vaccine Types
Figure 1-2: Advantages Of Targeting Neoantigens In Cancer Vaccine Development
Figure 2-1: Personalized Cancer Vaccine - Mechanism
Figure 2-2: Demonstrating Genomic Polymorphism In Pharmacogenomics
Figure 2-3: Source of Pharmacological and Pharmacogenetic Variability
Figure 3-1: Biomarkers In Personalized Medicine
Figure 3-2: Roadmap For Developing Predictive Biomarkers
Figure 4-1: Provenge - Approval Year By Region
Figure 4-2: Provenge - Cost Per Unit and Supply (US$), March’2025
Figure 6-1: Global Personalized Cancer Vaccines Market - Future Outlook
Figure 7-1: KEYNOTE-942 Phase 2 Study (NCT03897881) - Initiation and Completion Year
Figure 7-2: BNT111-01 Phase 2 Study (NCT04526899) - Initiation and Completion Year
Figure 7-3: KEYNOTE-D36 Phase 2 Study (NCT05309421) - Initiation and Completion Year
Figure 7-4: MC210102 Phase 1 Study (NCT05269381) - Initiation and Completion Year
Figure 7-5: INTerpath-002 Phase 3 Study (NCT06077760) - Initiation and Completion Year
Figure 7-6: INTerpath-009 Phase 3 Study (NCT06623422) - Initiation and Completion Year
Figure 7-7: KEYNOTE-603 Phase 1 Study (NCT03313778) - Initiation and Completion Year
Figure 7-8: MCC-20915 Phase 2 Study (NCT05325632) - Initiation and Completion Year
Figure 7-9: FK-PC101-01 Phase 2 Study (NCT06636682) - Initiation and Completion Year
Figure 7-10: 19-039 Phase 1 Study (NCT04161755) - Initiation and Completion Year
Figure 7-11: IMCODE003 Phase 2 Study (NCT05968326) - Initiation and Completion Year
Figure 7-12: GT-30 Phase 1/2 Study (NCT04251117) - Initiation and Completion Year
Figure 7-13: QUILT 502 Phase 1/2 Study (NCT06253494) - Initiation and Completion Year
Figure 9-1: BioNTech - iNeST
Figure 9-2: BioVaxys - DPX and Haptenix Platforms
Figure 9-3: CureVac - proprietary mRNA technology
Figure 9-4: Evaxion -Proprietary Technologies
Figure 9-5: Geneos - GT-EPIC Platform
Figure 9-6: Moderna - mRNA Design Studio Features
Figure 9-7: myNEO Therapeutics - ImmunoEngine
Figure 9-8: Nouscom - Unnamed Technology
Figure 9-9: Nykode Therapeutics - Vaccibody Structure
Figure 9-10: Nykode Therapeutics - Vaccibody Mechanism Of Action
Figure 9-11: Transgene - myvac Platform
Figure 10-1: Global Personalized Cancer Vaccines Market - Drivers and Opportunities
Figure 10-2: Global Personalized Cancer Vaccines Market - Challenges and Restraints
Table 5-1: Personalized Cancer Vaccines By Developer, Indication and Phase
Table 7-1: Melanoma - Personalized Vaccines In Clinical Trials
Table 7-2: Lung Cancer - Personalized Vaccines In Clinical Trials
Table 7-3: Breast Cancer - Personalized Vaccines In Clinical Trials
Table 7-4: Prostate Cancer - Personalized Vaccines In Clinical Trials
Table 7-5: Gastrointestinal Cancer - Personalized Vaccines In Clinical Trials
Table 7-6: Gynecological Cancer - Personalized Vaccines In Clinical Trials
Table 7-7: Brain Cancer - Personalized Vaccines In Clinical Trials
Table 7-8: Hematological Malignancies - Personalized Vaccines In Clinical Trials
